Navigation Links
Taglich Brothers Initiates Coverage on FluroPharma Medical, Inc.
Date:4/25/2013

New York, NY (PRWEB) April 25, 2013

FluoroPharma Medical, Inc. announces Taglich Brothers has initiated coverage.

FluoroPharma Medical, Inc.(FPMI: OTC BB), headquartered in Montclair, New Jersey, is a development stage enterprise founded in 2003 to develop pharmaceuticals based on technology licensed exclusively from the University of Massachusetts.

FPMI is focused on the development of radiopharmaceuticals used in positron emission tomography (PET) imaging scans that can more effectively detect and evaluate acute and chronic forms of coronary artery disease (CAD). Nuclear imaging scans are more effective diagnostic tools, as they can show changes in the function of an organ indicating disease or its progression more efficiently than the static images produced by conventional imaging modalities.

FluoroPharma Medical’s currently has three drug candidates. BFPET™ detects damaged tissue by measuring blood flow through the heart. CardioPET™ detects damaged heart tissue in CAD or suspected CAD patients unable to undergo conventional (exercise) stress tests. CardioPET is also useful in cardiac viability assessment (CVA) of patients prior to or after revascularization. BFPET and CardioPET are now in phase II trials. VasoPET™, still in preclinical development, aims to detect coronary artery plaque that is liable to break loose and lead to formation of clots that cause oxygen deprivation in the heart muscle, potentially causing a heart attack or stroke.

The complete 21-page report is available at http://www.taglichbrothers.com.

We do not undertake to advise you as to changes in figures or our views. This is not a solicitation of any order to buy or sell. Taglich Brothers, Inc. is fully disclosed with its clearing firm, Pershing, LLC, is not a market maker and does not sell to or buy from customers on a principal basis. The above statement is the opinion of Taglich Brothers, Inc. and is not a guarantee that the target price for the stock will be met or that predicted business results for the company will occur. There may be instances when fundamental, technical and quantitative opinions contained in this report are not in concert. We, our affiliates, any officer, director or stockholder or any member of their families may from time to time purchase or sell any of the above-mentioned or related securities. Analysts and members of the Research Department are prohibited from buying or selling securities issued by the companies that Taglich Brothers, Inc. has a research relationship with, except if ownership of such securities was prior to the start of such relationship, then an Analyst or member of the Research Department may sell such securities after obtaining expressed written permission from Compliance. As of the date of this report no Taglich Brothers, Inc. employees had a position in the stock of the company mentioned in this report.

All research issued by Taglich Brothers, Inc. is based on public information. In March 2013 the company paid an initial monetary engagement fee of US$4,500 to Taglich Brothers, Inc. representing payment for the first three months of creation and dissemination of research reports, after which the company will pay Taglich Brothers, Inc. a monetary fee of US$1,500 per month for a minimum of three more months for such services.

For further information and Taglich Brothers, Inc. ownership data please refer to each individual report.

Contact:
Richard Oh
Taglich Brothers, Inc.
631-757-1500

Read the full story at http://www.prweb.com/releases/taglichbrothers/equityuniverse/prweb10671030.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. PLC Medical Systems To Present At Taglich Brothers 10th Annual Small Cap Equity Conference
2. Derma Sciences To Present At Taglich Brothers 10th Annual Small Cap Equity Conference
3. Fluoropharma Medical To Present At Taglich Brothers 10th Annual Small Cap Equity Conference
4. Aeolus Pharmaceuticals To Present At Taglich Brothers 10th Annual Small Cap Equity Conference
5. South Charlotte Dentistry Initiates New Emphasis on Comprehensive Dental Treatment
6. UK initiates first cancer reporting model of its kind in US
7. Study finds newspapers have changed coverage of ice hockey concussions over last quarter-century
8. WINFertility Treatment Program Expands to Central/Southern Texas. Program Makes IVF Treatment More Affordable for Patients Without Infertility Insurance Coverage.
9. News Coverage of Shootings May Boost Stigma of Mental Illness
10. Media coverage of mass shootings contributes to negative attitudes towards mental illness
11. New Englanders Without IVF Coverage Have a More Affordable Way to Seek Help Through the WINFertility® Treatment Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... ... related services to families and business owners across eastern Michigan, is connecting with ... families struggling with financial difficulties. , The Oxford/Orion FISH Food Pantry works to ...
(Date:3/24/2017)... ... March 24, 2017 , ... Northridge ... now offering treatments for sleep apnea and TMJ at their office. TMJ, or ... , specifically the obstructive type, is increasingly being treated at dental offices with ...
(Date:3/24/2017)... ... March 24, 2017 , ... Gastro Health (“GH”) ... prep patients for colonoscopy at the HyGIeaCare® Center that is to be located ... , The HyGIeaCare® Prep, cleared by the U.S. Food and Drug ...
(Date:3/24/2017)... , ... March 24, 2017 , ... “End Time GPS”: ... salient events will interrelate. “End Time GPS” is the creation of published author, ... expert while working on military munitions and space-vehicle projects. Now, at age ninety-one, he ...
(Date:3/23/2017)... , ... March 23, 2017 , ... In 2016 the ... estimates that there could be four million Zika-related cases in the Americas within the ... numbers of US cases reported per year skyrocketing to an estimated 329,000. Yet, Zika, ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... YORK , March 24, 2017   ... leading organization within medical affairs in the pharmaceutical ... as the chair of a newly formed scientific ... board members to form the first ever medical ... For more information about the ACMA, please ...
(Date:3/24/2017)... -- Research and Markets has announced the addition of the ... their offering. ... pipeline is very strong with a total of 97 drug candidates. Pharma ... Sanofi are involved in the development of the IPF therapeutics. The IPF ... III stage, 15 are in Phase II stage, 12 are in Phase ...
(Date:3/24/2017)... Today Stock-Callers.com have issued research reports ... Inc. (NASDAQ: NVCN), Hologic Inc. (NASDAQ: HOLX), Edwards Lifesciences Corp. ... ). These companies are part of the Healthcare sector, which ... 23 rd , 2017, with the NYSE Health Care Index ... companies in the S&P 500 were down about 0.4% as ...
Breaking Medicine Technology: